International Journal of Heart Failure

The Korean Society of Heart Failure (대한심부전학회)
권호 표지
DOI QR코드

DOI QR Code

Heart Failure With Preserved Ejection Fraction and Atrial Fibrillation: Are Beta-Blockers Still Relevant?

  • Junho Hyun (Division of Cardiology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2024.07.14
  • Accepted : 2024.07.16
  • Published : 2024.07.30
Download PDF
⟨ Previous Next ⟩

Abstract

Keywords

References

  1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022;145:e895-1032. https://doi.org/10.1161/CIR.0000000000001073
  2. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-726. https://doi.org/10.1093/eurheartj/ehab368
  3. Youn JC, Kim D, Cho JY, et al. Korean Society of Heart Failure guidelines for the management of heart failure: treatment. Int J Heart Fail 2023;5:66-81.
  4. Topol EJ, Traill TA, Fortuin NJ. Hypertensive hypertrophic cardiomyopathy of the elderly. N Engl J Med 1985;312:277-83. https://doi.org/10.1056/NEJM198501313120504
  5. Silverman DN, Plante TB, Infeld M, et al. Association of β-blocker use with heart failure hospitalizations and cardiovascular disease mortality among patients with heart failure with a preserved ejection fraction: a secondary analysis of the TOPCAT trial. JAMA Netw Open 2019;2:e1916598.
  6. Yamamoto K, Origasa H, Hori M; J-DHF Investigators. Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013;15:110-8. https://doi.org/10.1093/eurjhf/hfs141
  7. Rosano GM, Vitale C, Spoletini I. Precision cardiology: phenotype-targeted therapies for HFmrEF and HFpEF. Int J Heart Fail 2024;6:47-55. https://doi.org/10.36628/ijhf.2023.0058
  8. Meyer M, LeWinter MM. Heart rate and heart failure with preserved ejection fraction: time to slow β-blocker use? Circ Heart Fail 2019;12:e006213.
  9. Conraads VM, Metra M, Kamp O, et al. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: results of the ELANDD study. Eur J Heart Fail 2012;14:219-25. https://doi.org/10.1093/eurjhf/hfr161
  10. Palau P, Seller J, Dominguez E, et al. Effect of β-blocker withdrawal on functional capacity in heart failure and preserved ejection fraction. J Am Coll Cardiol 2021;78:2042-56. https://doi.org/10.1016/j.jacc.2021.08.073
  11. van Veldhuisen DJ, Cohen-Solal A, Bohm M, et al. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol 2009;53:2150-8. https://doi.org/10.1016/j.jacc.2009.02.046
  12. Cleland JGF, Bunting KV, Flather MD, et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J 2018;39:26-35. https://doi.org/10.1093/eurheartj/ehx564
  13. Zakeri R, Chamberlain AM, Roger VL, Redfield MM. Temporal relationship and prognostic significance of atrial fibrillation in heart failure patients with preserved ejection fraction: a community-based study. Circulation 2013;128:1085-93. https://doi.org/10.1161/CIRCULATIONAHA.113.001475
  14. Kim YI, Ahn MS, Yoo BS, et al. Differences in the effects of beta-blockers depending on heart rate at discharge in patients with heart failure with preserved ejection fraction and atrial fibrillation. Int J Heart Fail 2024;6:120-7.
  15. Yang Y, Guo S, Huang Z, et al. Decreased mortality with beta-blocker therapy in HFpEF patients associated with atrial fibrillation. Cardiol Res Pract 2020;2020:3059864.
  16. Lam PH, Gupta N, Dooley DJ, et al. Role of high-dose beta-blockers in patients with heart failure with preserved ejection fraction and elevated heart rate. Am J Med 2018;131:1473-81. https://doi.org/10.1016/j.amjmed.2018.07.008
  17. Ahn MS, Yoo BS, Son JW, et al. Beta-blocker therapy at discharge in patients with acute heart failure and atrial fibrillation. J Korean Med Sci 2020;35:e278.
  18. Rillig A, Magnussen C, Ozga AK, et al. Early rhythm control therapy in patients with atrial fibrillation and heart failure. Circulation 2021;144:845-58. https://doi.org/10.1161/CIRCULATIONAHA.121.056323
  19. Peikert A, Bart BA, Vaduganathan M, et al. Contemporary use and implications of beta-blockers in patients with HFmrEF or HFpEF: the DELIVER trial. JACC Heart Fail 2024;12:631-44.